Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Jolanda Howe Sells 2,721 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Jolanda Howe sold 2,721 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $120.00, for a total value of $326,520.00. Following the completion of the transaction, the senior vice president owned 3,114 shares of the company’s stock, valued at $373,680. The trade was a 46.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jolanda Howe also recently made the following trade(s):

• On Wednesday, June 17th, Jolanda Howe sold 2,594 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $101.95, for a total value of $264,458.30.

Mirum Pharmaceuticals Stock Up 4.3%

Shares of NASDAQ:MIRM opened at $125.59 on Friday. The stock’s 50-day moving average price is $102.58 and its two-hundred day moving average price is $95.56. The company has a current ratio of 2.09, a quick ratio of 1.99 and a debt-to-equity ratio of 1.28. Mirum Pharmaceuticals, Inc. has a 12-month low of $49.01 and a 12-month high of $125.75. The firm has a market cap of $7.66 billion, a price-to-earnings ratio of -9.23 and a beta of 0.48.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($13.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($12.68). Mirum Pharmaceuticals had a negative net margin of 140.24% and a negative return on equity of 11.28%. The company had revenue of $159.88 million for the quarter, compared to analyst estimates of $148.21 million. During the same period in the prior year, the company earned ($0.30) EPS. The company’s revenue was up 43.3% compared to the same quarter last year. On average, research analysts forecast that Mirum Pharmaceuticals, Inc. will post -2.01 EPS for the current year.

Institutional Trading of Mirum Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC boosted its holdings in Mirum Pharmaceuticals by 21.4% in the 4th quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company’s stock worth $479,050,000 after acquiring an additional 1,067,722 shares during the period. State Street Corp lifted its position in shares of Mirum Pharmaceuticals by 59.2% during the fourth quarter. State Street Corp now owns 2,143,992 shares of the company’s stock worth $169,354,000 after purchasing an additional 797,088 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of Mirum Pharmaceuticals by 566.8% in the third quarter. Wellington Management Group LLP now owns 790,689 shares of the company’s stock valued at $57,965,000 after purchasing an additional 672,118 shares during the period. Arrowstreet Capital Limited Partnership grew its holdings in Mirum Pharmaceuticals by 709.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 612,318 shares of the company’s stock valued at $44,889,000 after purchasing an additional 536,674 shares in the last quarter. Finally, Voloridge Investment Management LLC increased its stake in Mirum Pharmaceuticals by 2,116.6% during the 3rd quarter. Voloridge Investment Management LLC now owns 389,574 shares of the company’s stock worth $28,560,000 after buying an additional 371,999 shares during the period.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. Robert W. Baird increased their price target on shares of Mirum Pharmaceuticals from $112.00 to $129.00 and gave the stock an “outperform” rating in a research note on Thursday, May 7th. Morgan Stanley boosted their price objective on shares of Mirum Pharmaceuticals from $140.00 to $150.00 and gave the company an “overweight” rating in a research note on Thursday, June 11th. JPMorgan Chase & Co. upped their price objective on Mirum Pharmaceuticals from $115.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday. CLSA set a $146.00 target price on Mirum Pharmaceuticals in a research report on Monday, June 15th. Finally, Raymond James Financial reissued a “strong-buy” rating and set a $165.00 price target on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $143.00.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.